Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers

KRAS mutations are prevalent in pancreatic and lung cancers, but not all mutant (mt) KRAS tumors are addicted to mt KRAS. Here, we discovered a 30-gene transcriptome signature “KDS30” that encodes a novel EGFR/ERBB2-driven signaling network and predicts mt KRAS, but not NRAS or HRAS, oncogene addict...

Descripción completa

Detalles Bibliográficos
Autores principales: Tyc, Katarzyna M., Kazi, Aslamuzzaman, Ranjan, Alok, Wang, Rui, Sebti, Said M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958355/
https://www.ncbi.nlm.nih.gov/pubmed/36852277
http://dx.doi.org/10.1016/j.isci.2023.106082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958355/
https://www.ncbi.nlm.nih.gov/pubmed/36852277
http://dx.doi.org/10.1016/j.isci.2023.106082

Ejemplares similares